Janssen Research

 
News Articles for Janssen Research top ^
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults TITUSVILLE, N.J. , Nov.
Sign-up for Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate investment picks
2014/11/4
LONDON , SUNNYVALE, Calif.
Sign-up for AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers investment picks
2015/1/21
NEW BRUNSWICK, N.J. , Jan.
Sign-up for Dr. Paul Janssen Award for Biomedical Research Issues 2015 Call for Nominations investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced an expansion to its agreement with Janssen R&D Ireland for the development and commercialization of a new once-daily single tablet regimen containing Gilead’s tenofovir alafenamide (TAF) and emtricitabine, and Janssen’s rilpivirine.
Sign-up for Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment investment picks
Sevion Therapeutics Inc. ("Sevion" or the "Company") (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics, today announced a collaboration agreement with CNA Development, LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) to discover antibodies using Sevion’s spatially addressed library platform.
Sign-up for Sevion Announces Antibody Discovery Collaboration with Johnson & Johnson Innovation and Janssen investment picks
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation --
Sign-up for Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract investment picks
Conference call today at 5:00 p.m. EST - Transformative acquisition enhances Depomed's position as a leading pain and neurology focused specialty pharmaceutical company - Adds significant revenue and immediate earnings impact upon expected second quarter closing; increases Depomed 2014 pro forma net product revenues by approximately 2.5 times compared to recent company guidance - Expected to be immediately accretive to non-GAAP EPS in 2015, with significant growth in net sales, EBITDA, non-GAAP earnings and cash flow beyond that timeframe - Strong fundamental returns - return on invested capital estimated to exceed cost of capital by 2016 - Directly leverages Depomed's existing infrastructure and expertise with pain specialists, neurologists and primary care physicians - Intellectual property provides lengthy period of market exclusivity NEWARK, Calif.
Sign-up for Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Janssen Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Janney Capital Markets  |  Next: Japan Asia